Search results
Results From The WOW.Com Content Network
The UK-based pharmaceutical firm, known for its popular cancer drugs, entered the Covid-19 crisis with little experience developing vaccines. And the success of Vaxzevria was far from guaranteed .
The Financial Times reported this was comprised of £70m in grants to develop an existing AstraZeneca facility at the same location, plus £20m in research and development support from the UK ...
AstraZeneca has cancelled a planned £450 million investment in a vaccine manufacturing plant in Merseyside, saying Labour failed to match the previous government’s offer of support.
A packet of AstraZeneca COVID-19 vaccine vials. A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, [1] and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol.
On 27 December 2020, AstraZeneca CEO Pascal Soriot said that they have “figured out the winning formula” with their two-dose system with the Oxford University’s COVID-19 vaccine. [82] Three days later, the United Kingdom approved the emergency use of the Oxford–AstraZeneca COVID-19 vaccine. [83] [84] [85]
In January 2022, New Scientist reported Sky News-sourced speculation that, "within the coming weeks", the government was expected to announce plans to transition to treating COVID-19 as endemic in the UK. [162] Prime Minister Boris Johnson announced in February 2022 that remaining restrictions would end in England, under a "Living with COVID" plan.
AstraZeneca ditches £450m investment in UK plant. January 31, 2025 at 10:39 AM. AstraZeneca has scrapped plans to invest £450m in expanding a vaccine manufacturing plant in Liverpool, blaming a ...
British finance minister Rachel Reeves wants to reduce state provisions to the company's vaccine centre, which will cut the pledge made by the previous administration from about 90 million pounds ...